LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 455

Search options

  1. Article ; Online: Take an inch for a mile. About an error of metrics in WTO rules and its impact on the ability of countries to build public stocks for food security

    Galtier, Franck

    Food Policy. 2023 Apr., v. 116 p.102400-

    2023  

    Abstract: Many developing countries use public stocks to provide free or subsidised grain to food-insecure households or to mitigate sharp increases in grain prices. However, the building of public stocks is regulated by the WTO, as public procurement may be used ... ...

    Abstract Many developing countries use public stocks to provide free or subsidised grain to food-insecure households or to mitigate sharp increases in grain prices. However, the building of public stocks is regulated by the WTO, as public procurement may be used to provide farmers with a price support. This support is bounded jointly with the other forms of non-exempt domestic support for agriculture. Since 2012, WTO rules on public stockholding programmes have been questioned by a group of 33 member countries, and are at the top of the WTO negotiation agenda. The topics debated are i) the way this support should be calculated, and ii) the maximum level of support allowed. This article addresses the first topic. It identifies three biases in WTO rules and estimates the magnitude of the gap between the support actually provided and the support calculated according to WTO rules. It appears that, for grains, the support calculated is generally several times higher than the real support, compromising countries’ compliance with their domestic support commitments and thereby significantly reducing their ability to build public stocks. Moreover, the gap is not the same for all countries and is generally much higher for poor countries: the countries that most need public stocks for food security are those with the least freedom to build them. This article thus proposes a simple way to correct the rules that specify how the support provided by public stockholding programmes should be calculated.
    Keywords agricultural subsidies ; compliance ; food policy ; food security ; Food reserve ; Public stock ; WTO ; Agreement on Agriculture ; Domestic support
    Language English
    Dates of publication 2023-04
    Publishing place Elsevier Ltd
    Document type Article ; Online
    ZDB-ID 194840-4
    ISSN 0306-9192
    ISSN 0306-9192
    DOI 10.1016/j.foodpol.2022.102400
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article ; Online: Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta-analysis.

    Diallo, A / Diallo, M F / Carlos-Bolumbu, M / Galtier, F

    Diabetes, obesity & metabolism

    2024  Volume 26, Issue 5, Page(s) 1980–1985

    Abstract: Background: To evaluate the effect of a 1 mg/dl reduction in uric acid (UA) on cardiovascular events and mortality in patients treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors.: Research design and methods: We performed a systematic ... ...

    Abstract Background: To evaluate the effect of a 1 mg/dl reduction in uric acid (UA) on cardiovascular events and mortality in patients treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors.
    Research design and methods: We performed a systematic review of the MEDLINE and EMBASE databases searched up to 30 June 2023 (PROSPERO, CRD42022355479) to identify large-scale SGLT2 inhibitor trials. Random-effects meta-analyses were used to pool the estimates.
    Results: In total, five SGLT2 inhibitor trials (31 535 patients, 54% with heart failure) were analysed. Over a median follow-up of 2.2 years, the mean reduction in UA was -0.79 mg/dl (95% confidence interval (CI), -1.03 to -0.54). Every 1 mg/dl reduction in UA was associated with a significantly lower risk of a composite of cardiovascular death and hospitalization for heart failure [hazard ratio, 0.64 (95% CI, 0.46-0.88)] and hospitalization for heart failure (0.68; 95% CI, 0.62-0.74), with a similar risk of mortality.
    Conclusions: SGLT2 inhibitors reduced UA levels and cardiovascular events independently of heart failure status.
    MeSH term(s) Humans ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Cardiovascular Diseases/complications ; Uric Acid ; Heart Failure/prevention & control ; Heart Failure/complications ; Glucose ; Sodium
    Chemical Substances Sodium-Glucose Transporter 2 Inhibitors ; Uric Acid (268B43MJ25) ; Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27)
    Language English
    Publishing date 2024-02-05
    Publishing country England
    Document type Meta-Analysis ; Systematic Review ; Letter
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15483
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Is composite cardiovascular death or hospitalization for heart failure a valid surrogate for mortality in patients treated with sodium-glucose cotransporter 2 inhibitors? A correlation meta-analysis.

    Diallo, Alhassane / Carlos-Bolumbu, Miguel / Galtier, Florence

    Diabetes, obesity & metabolism

    2023  Volume 26, Issue 1, Page(s) 392–395

    MeSH term(s) Humans ; Cardiovascular Diseases ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Glucose ; Heart Failure/drug therapy ; Hospitalization ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
    Chemical Substances Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27) ; Sodium-Glucose Transporter 2 Inhibitors
    Language English
    Publishing date 2023-10-18
    Publishing country England
    Document type Meta-Analysis ; Letter
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15320
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.

    Diallo, Alhassane / Carlos-Bolumbu, Miguel / Galtier, Florence

    Acta diabetologica

    2023  Volume 60, Issue 12, Page(s) 1651–1662

    Abstract: Aims: To investigate the lowering BP effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on the risk of major cardiovascular event stratified by glucose-lowering drugs, baseline BP, ... ...

    Abstract Aims: To investigate the lowering BP effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on the risk of major cardiovascular event stratified by glucose-lowering drugs, baseline BP, glycated hemoglobin (HbA
    Methods: We performed a systematic review of the MEDLINE and EMBASE databases search up to December 31, 2022, (PROSPERO, CRD42023400899) to identify all large-scale cardiovascular outcomes (CVO) trials of SGLT2i and GLP-1 RAs in which more than 1,000 patient-years of follow-up in each randomized group. Outcomes included all-cause mortality, major adverse cardiovascular event (MACE) and its component (cardiovascular death, myocardial infarction [MI], and stroke), heart failure, and renal failure. A random-effects meta-analyses were used to pool the estimates.
    Results: Eighteen CVOTs (ten for SGLT2i and eight for GLP-1 RAs) with 127,606 patients with type 2 diabetes were included. Over 2.5 years median follow-up, the average reduction of systolic BP was 2.2 mmHg (mean difference [MD] - 2.2; 95% CI - 2.7 to - 1.7) with more important reduction (P
    Conclusion: In patients with type 2 diabetes, the hypotensive effects of SGLT2i and GLP-1 RAs were significantly associated with a reduction in mortality and cardiorenal events. These findings suggest that the lowering BP effect could be seen as an additive indicator of cardiovascular protection by SGLT2i and GLP-1 RAs drugs.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Glucagon-Like Peptide-1 Receptor ; Blood Pressure ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Heart Failure/complications ; Myocardial Infarction/complications ; Glucagon-Like Peptide 1 ; Stroke/complications ; Renal Insufficiency/chemically induced ; Renal Insufficiency/complications ; Hypoglycemic Agents/therapeutic use
    Chemical Substances Sodium-Glucose Transporter 2 Inhibitors ; Glucagon-Like Peptide-1 Receptor ; Glucagon-Like Peptide 1 (89750-14-1) ; Hypoglycemic Agents
    Language English
    Publishing date 2023-07-13
    Publishing country Germany
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 1097676-0
    ISSN 1432-5233 ; 0940-5429
    ISSN (online) 1432-5233
    ISSN 0940-5429
    DOI 10.1007/s00592-023-02154-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis.

    Diallo, Alhassane / Carlos-Bolumbu, Miguel / Galtier, Florence

    EClinicalMedicine

    2022  Volume 54, Page(s) 101697

    Abstract: Background: Summarized data of cardiovascular outcomes trials (CVOTs) of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have shown a reduction in major adverse cardiovascular event (MACE), ... ...

    Abstract Background: Summarized data of cardiovascular outcomes trials (CVOTs) of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have shown a reduction in major adverse cardiovascular event (MACE), whether these benefits are extended in certain risk groups (elderly or obese patients or those with a longer duration of diabetes) or certain minorities (Black participants) are not clearly established. We aimed to provide overall hazard ratios (HRs) estimates for MACE of SGLT2i and GLP-1 RAs stratified by age (< 65 years vs. ≥ 65 years and < 75 years vs. ≥ 75 years), sex (male vs. female), race (Black vs. White, Black vs. Asian, and White vs. Asian), body mass index (BMI: < 30 kg/m
    Methods: We performed a MEDLINE database search from inception up to July 31, 2022 to identify all placebo-controlled phase 3 CVOTs that evaluated the efficacy of SGLT2i and GLP-1 RAs on vascular events at least 1-year after randomisation in participants with type 2 diabetes, and we selected those reporting hazard ratios (HRs) for the specific risk groups for MACE. Differences on MACE in risk groups were examined using a random-effect meta-analysis. The study protocol was registered on PROSPERO (CRD42022347901).
    Findings: A total of 11 studies fulfilled the prespecified criteria, comprising 96,580 patients with T2D were included. Of these patients, 61,975 (64.2%) were male, 34,605 (35.8%) were female, and race groups included 74,982 (77.6%) White, 7760 (8.0%) Asian, and 4023 (4.2%) Black. In two SGLT2i trials, the HR (95% CI) for long-term diabetes duration more than10 years versus short duration was 0.84 (0.77-0.93) vs. 1.02 (0.89-1.16), respectively (
    Interpretation: In patients with type 2 diabetes at highest risk of cardiovascular disease or established cardiovascular disease, a greater benefit on MACE was found for elderly patients and for Asian individuals compared with White individuals with GLP-1 RAs, and those with a long duration of diabetes with SGLT2i. These findings could help in providing guidance for treatment prescription and facilitate selection and stratification of patients for future CVOTs. Furthermore, pooled individual patient-level data are urgently needed to support our conclusions, and to derive definitive evidence.
    Funding: None.
    Language English
    Publishing date 2022-10-12
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2022.101697
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Effects of hypoglycaemic agents on reducing surrogate metabolic parameters for the prevention of cardiovascular events and death in patients with type 2 diabetes: A systematic review and meta-analysis.

    Diallo, Alhassane / Villard, Orianne / Carlos-Bolumbu, Miguel / Renard, Eric / Galtier, Florence

    Diabetes, obesity & metabolism

    2023  Volume 26, Issue 2, Page(s) 495–502

    Abstract: Aims: To investigate the impact of glucose-lowering therapy-induced glycated haemoglobin (HbA1c) reduction on the risk of major clinical events according to body weight change and, as a secondary objective, to evaluate the impact of concomitant ... ...

    Abstract Aims: To investigate the impact of glucose-lowering therapy-induced glycated haemoglobin (HbA1c) reduction on the risk of major clinical events according to body weight change and, as a secondary objective, to evaluate the impact of concomitant reductions in HbA1c and body weight on major clinical events.
    Materials and methods: We searched the MEDLINE and EMBASE databases up to June 30, 2022, for large-scale studies on glucose-lowering therapies in which more than 1000 patient-years of follow-up in each randomized group were completed. The primary outcome was all-cause mortality. The study was registered in PROSPERO (CRD42022355479).
    Results: Thirty-four trials involving 227 220 patients with type 2 diabetes were meta-analysed using a random-effects model. Each 1% reduction in HbA1c was associated with a different risk of mortality depending on the ability of glucose-lowering therapies to induce body weight loss or gain. When glucose-lowering therapies were associated with weight gain, the risk of mortality increased by 8% (hazard ratio [HR] 1.08, 95% confidence interval [CI] 1.00-1.16) for each 1% reduction in HbA1c. When glucose-lowering therapies were associated with weight loss, the risk of mortality was reduced by 22% (HR 0.78, 95% CI 0.72-0.85) for each 1% reduction in HbA1c. In addition, concomitant reductions in HbA1c and body weight were associated with a significantly lower risk of mortality and vascular events.
    Conclusions: In patients with type 2 diabetes, concomitant reductions in HbA1c and body weight might be more effective in preventing the risk of vascular events and mortality.
    MeSH term(s) Humans ; Hypoglycemic Agents/therapeutic use ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Glycated Hemoglobin ; Glucose/therapeutic use ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/chemically induced ; Body Weight
    Chemical Substances Hypoglycemic Agents ; Glycated Hemoglobin ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2023-10-23
    Publishing country England
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15335
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.

    Diallo, Alhassane / Carlos-Bolumbu, Miguel / Renard, Pr Eric / Galtier, Florence

    Diabetes, obesity & metabolism

    2022  Volume 25, Issue 1, Page(s) 166–176

    Abstract: Aim: To compare treatment effect sizes between a composite kidney outcome (CKO) and three-point major adverse cardiovascular event (MACE-3) outcomes with use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor ... ...

    Abstract Aim: To compare treatment effect sizes between a composite kidney outcome (CKO) and three-point major adverse cardiovascular event (MACE-3) outcomes with use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), and to investigate the relationship between treatment effects on CKO and MACE-3 in patients with type 2 diabetes (T2D).
    Materials and methods: We performed a MEDLINE database search up to December 31, 2021 to identify all placebo-controlled Phase 3 trials which investigated the efficacy of glucose-lowering interventions, and selected those reporting results for CKO and MACE-3. Hazard ratios (HRs) with 95% confidence intervals (CIs) for both outcomes were extracted for each trial, and we evaluated differences in treatment effect sizes by using a ratio of HRs (rHR): the HR for CKO to the HR for MACE-3. A random-effects meta-analysis was used to obtain the overall rHR across trials and according to subgroup. We investigated the relationship between treatment effects on CKO and MACE-3 using the coefficient of determination (R
    Results: A total of 12 studies fulfilled the prespecified criteria, and comprised a total of 104 987 patients with T2D. On average, treatment effect sizes were 17% greater for CKO than for MACE-3 (rHR 0.83, 95% CI 0.74 to 0.92; I
    Conclusion: In T2D patients, treatment effect sizes were greater for kidney than for macrovascular (MACE-3) outcomes, with important differences according to the drugs considered. CKO and MACE-3 are independent. Caution must be taken when interpreting CKO in the absence of MACE-3 data.
    MeSH term(s) Humans ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide-1 Receptor/agonists ; Kidney ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Clinical Trials, Phase III as Topic ; Randomized Controlled Trials as Topic
    Chemical Substances Glucagon-Like Peptide-1 Receptor ; Sodium-Glucose Transporter 2 Inhibitors
    Language English
    Publishing date 2022-09-23
    Publishing country England
    Document type Meta-Analysis ; Journal Article
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.14859
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Definition, epidemiology, risk factors.

    Galtier, F

    Diabetes & metabolism

    2010  Volume 36, Issue 6 Pt 2, Page(s) 628–651

    Abstract: Gestational diabetes mellitus is defined as glucose intolerance that begins or is first recognized during pregnancy. Its prevalence, generally situated between 2-6%, may reach 10-20% in high-risk populations, with an increasing trend across most racial/ ... ...

    Abstract Gestational diabetes mellitus is defined as glucose intolerance that begins or is first recognized during pregnancy. Its prevalence, generally situated between 2-6%, may reach 10-20% in high-risk populations, with an increasing trend across most racial/ethnic groups studied. Among traditional risk factors, previous gestational diabetes, advanced maternal age and obesity have the highest impact on gestational diabetes risk. Racial/ethnic origin and family history of type 2 diabetes have a significant but moderate impact (except for type 2 diabetes in siblings). Several non traditional factors have been recently characterized, either physiological (low birthweight and short maternal height) or pathological (polycystic ovaries). The multiplicity of risk factors and their interactions results in a low reliability of risk prediction on an individual basis.
    MeSH term(s) Diabetes, Gestational/diagnosis ; Diabetes, Gestational/epidemiology ; Female ; Humans ; Pregnancy ; Risk Factors
    Language English
    Publishing date 2010-12
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 1315751-6
    ISSN 1878-1780 ; 1262-3636 ; 0338-1684
    ISSN (online) 1878-1780
    ISSN 1262-3636 ; 0338-1684
    DOI 10.1016/j.diabet.2010.11.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Définitions, épidémiologie, facteurs de risque.

    Galtier, F

    Journal de gynecologie, obstetrique et biologie de la reproduction

    2010  Volume 39, Issue 8 Suppl 2, Page(s) S144–70

    Abstract: Gestational diabetes mellitus is defined as carbohydrate intolerance that begins or is first recognized during pregnancy. Its prevalence, generally situated between 2-6%, may reach 10-20% in high-risk populations, with an increasing trend across most ... ...

    Title translation Definitions, epidemiology, risk factors.
    Abstract Gestational diabetes mellitus is defined as carbohydrate intolerance that begins or is first recognized during pregnancy. Its prevalence, generally situated between 2-6%, may reach 10-20% in high-risk populations, with an increasing trend across most racial/ethnic groups studied. Among classical risk factors, previous gestational diabetes, older maternal age and obesity have the most important impact on gestational diabetes risk. Racial/ethnic origin and family history of type 2 diabetes have a significant but moderate impact (except for type 2 diabetes in siblings). Several non classical factors have been recently characterized, either physiological (low birth weight and short maternal height) or pathological (polycystic ovaries). The multiplicity of risk factors and their interactions results in a low reliability of risk prediction on an individual basis.
    MeSH term(s) Diabetes, Gestational/diagnosis ; Diabetes, Gestational/epidemiology ; Diabetes, Gestational/etiology ; Female ; Humans ; Pregnancy ; Prevalence ; Risk Factors
    Language French
    Publishing date 2010-12
    Publishing country France
    Document type English Abstract ; Journal Article
    ZDB-ID 121670-3
    ISSN 1773-0430 ; 0368-2315 ; 0150-9918
    ISSN (online) 1773-0430
    ISSN 0368-2315 ; 0150-9918
    DOI 10.1016/S0368-2315(10)70044-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Book ; Article ; Online: Identifying, estimating and correcting the biases in WTO rules on public stocks. A proposal for the post-Bali food security agenda ; Identifier, estimer et corriger les biais des règles de l’OMC sur les stocks publics. Une proposition pour l’agenda post-Bali sur la sécurité alimentaire

    Galtier, Franck

    2015  

    Abstract: In this paper, we analyse the WTO rules that specify how the subsidy provided to farmers by public stocks should be estimated. We identify three biases in these rules: - Bias B1, resulting from the use of a fixed past unit value of imports or exports as ... ...

    Abstract In this paper, we analyse the WTO rules that specify how the subsidy provided to farmers by public stocks should be estimated. We identify three biases in these rules: - Bias B1, resulting from the use of a fixed past unit value of imports or exports as the external reference price, instead of the current price cost of imports or exports. - Bias B2, resulting from the use of the public stock procurement price instead of the price prevailing on the domestic market to estimate the price support received by farmers selling their production on the domestic market. - Bias B3, resulting from the use of total national production instead of the marketed share of national production, thereby ignoring farmers’ self-consumption. The effect of these three biases on the estimated subsidy varies from country to country, but on average, WTO rules result in the subsidy being overestimated by a factor of between 2 and more than 300, depending on public stock intervention modalities and country characteristics. This means that in the most favourable scenarios, the estimated subsidy is (on average) twice the real subsidy. These biases have a huge effect on country compliance: many countries have an estimated subsidy that exceeds their maximum allowed level (even with very limited public stock interventions), simply because the subsidy provided by public stocks is overestimated by WTO rules. This result challenges the widespread idea that almost all countries comply with WTO rules on public stocks. We also test the effect of individually correcting biases B1, B2 and B3. It appears that doing so would not eliminate the bias on country compliance. One implication of this is that expressing the fixed external reference price (FERP) in US dollars, correcting it with the country inflation rate or replacing it by the average unit value of imports or exports over the last five years (as proposed by some experts and WTO Members) would not be enough to remove the bias on country compliance. It is therefore necessary to correct all three biases, which can be achieved in a rather simple manner, as shown at the end of the paper.
    Keywords World Trade Organization ; Doha Round ; Bali Agreement ; Public stock ; Subsidy ; Domestic support ; Organisation Mondiale du Commerce ; Cycle de Doha ; Accord de Bali ; Stock public ; Subvention ; Soutien interne ; Agricultural and Food Policy ; International Relations/Trade ; Q18 ; Q11 ; F1
    Subject code 381
    Language English
    Publishing country us
    Document type Book ; Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top